<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>L-2-Hydroxyglutaric Aciduria - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>L-2-Hydroxyglutaric Aciduria</span>
        </nav>

        <header class="page-header">
            <h1>L-2-Hydroxyglutaric Aciduria</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0009370" target="_blank">
                        MONDO:0009370
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Organic Acidemia</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                L-2-Hydroxyglutaric aciduria (L2HGA) is a rare autosomal recessive neurometabolic disorder caused by biallelic pathogenic variants in the L2HGDH gene, which encodes a mitochondrial FAD-dependent L-2-hydroxyglutarate dehydrogenase. Loss of this metabolite-repair enzyme leads to systemic accumulation of L-2-hydroxyglutarate (L-2-HG), particularly in the brain and cerebrospinal fluid. The disease follows a slowly progressive course characterized by psychomotor delay, intellectual disability, epilepsy, cerebellar ataxia, and movement disorders. Brain MRI shows a distinctive pattern of subcortical white matter abnormalities with basal ganglia and dentate nuclei involvement. L2HGA patients also have an increased lifetime risk of central nervous system tumors. Treatment is primarily supportive with riboflavin and levocarnitine supplementation.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">14</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">L2HGDH enzymatic deficiency</div>
                
                <div class="item-desc">Pathogenic variants in L2HGDH reduce mitochondrial L-2-hydroxyglutarate dehydrogenase activity.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        L2HGDH
                        
                    </span>
                    
                </div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">L-2-hydroxyglutarate accumulation</div>
                
                <div class="item-desc">Loss of L-2-hydroxyglutarate dehydrogenase activity impairs the metabolite-repair pathway that clears L-2-hydroxyglutarate (L-2-HG), an aberrant off-pathway metabolite produced from alpha-ketoglutarate by L-malate dehydrogenase. L-2-HG accumulates in body fluids, particularly brain and CSF, at concentrations 10-300 times above normal.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        organic acid metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006082" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22391998" target="_blank">PMID:22391998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical hallmarks of these disorders."</div>
                
                
                <div class="evidence-explanation">Directly supports L-2-HG accumulation as the biochemical hallmark of L2HGA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">White-matter vulnerability and progressive leukoencephalopathy</div>
                
                <div class="item-desc">L-2-HG accumulation leads to selective vulnerability of subcortical cerebral white matter with basal ganglia and dentate nucleus involvement. In mouse models, L2HGDH deficiency causes progressive leukoencephalopathy with demyelination, extensive gliosis, microglia-mediated neuroinflammation, and expansion of oligodendrocyte progenitor cells.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        oligodendrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000128" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        microglial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        myelination
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042552" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        white matter
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002316" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        basal ganglion
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002420" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28137912" target="_blank">PMID:28137912</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"KO mice exhibit white matter abnormalities, extensive gliosis, microglia-mediated neuroinflammation, and an expansion of oligodendrocyte progenitor cells (OPCs)."</div>
                
                
                <div class="evidence-explanation">Mouse model demonstrates leukoencephalopathy, gliosis, neuroinflammation, and OPC expansion.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neuroradiological features of centripetal subcortical leukoencephalopathy with basal ganglia and dentate nuclei involvement are rather specific to L2HGA"</div>
                
                
                <div class="evidence-explanation">Human neuroimaging confirms the characteristic white matter and deep gray matter pattern.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mitochondrial dysfunction and metabolic reprogramming</div>
                
                <div class="item-desc">Elevated L-2-HG impairs mitochondrial bioenergetics, reducing maximal respiratory capacity and shifting neuronal cell metabolism toward anaerobic glycolysis. In neuronal cell models, L-2-HG exposure leads to decreased glucose uptake, increased lactate release, and reduced carbon flux through the TCA cycle.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        oxidative phosphorylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006119" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        glycolytic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006096" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        mitochondrion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005739" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38862727" target="_blank">PMID:38862727</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"both enantiomers of 2HG comparably stimulate anaerobic metabolism of glucose and inhibit the uptake of several essential amino acids from the culture media"</div>
                
                
                <div class="evidence-explanation">In vitro neuronal cell model demonstrates metabolic reprogramming under L-2-HG exposure.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Epigenetic dysregulation via inhibition of alpha-KG-dependent dioxygenases</div>
                
                <div class="item-desc">L-2-HG is a structural analog of alpha-ketoglutarate and can inhibit alpha-KG-dependent dioxygenases, including TET DNA hydroxylases and JmjC histone demethylases. In L2HGDH-deficient mouse brain, this manifests as increased histone methylation, linking metabolite accumulation to epigenetic perturbation.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        histone demethylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0016577" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        DNA demethylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0080111" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        nucleus
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005634" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38716347" target="_blank">PMID:38716347</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"These findings were against all our expectations given the inhibitory potential of 2-HG on DNA-demethylation enzymes."</div>
                
                
                <div class="evidence-explanation">L-2-HGA-associated glioma did NOT show the G-CIMP hypermethylation phenotype expected from dioxygenase inhibition, unlike IDH-mutant tumors with D-2-HG accumulation. This argues against a simple epigenetic oncogenic mechanism in L-2-HGA.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28137912" target="_blank">PMID:28137912</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"a corresponding increase in histone methylation in these tissues"</div>
                
                
                <div class="evidence-explanation">L2hgdh KO mice show increased histone methylation in brain, directly demonstrating that L-2-HG accumulation causes epigenetic dysregulation via inhibition of histone demethylases in vivo.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    White_matter_vulnerability_and_progressive_leukoencephalopathy[&#34;White-matter vulnerability and progressive leukoencephalopathy&#34;]
    L2HGDH_enzymatic_deficiency[&#34;L2HGDH enzymatic deficiency&#34;]
    Mitochondrial_dysfunction_and_metabolic_reprogramming[&#34;Mitochondrial dysfunction and metabolic reprogramming&#34;]
    L_2_hydroxyglutarate_accumulation[&#34;L-2-hydroxyglutarate accumulation&#34;]
    Epigenetic_dysregulation_via_inhibition_of_alpha_KG_dependent_dioxygenases[&#34;Epigenetic dysregulation via inhibition of alpha-KG-dependent dioxygenases&#34;]

    L2HGDH_enzymatic_deficiency --&gt; L_2_hydroxyglutarate_accumulation
    L_2_hydroxyglutarate_accumulation --&gt; White_matter_vulnerability_and_progressive_leukoencephalopathy
    L_2_hydroxyglutarate_accumulation --&gt; Mitochondrial_dysfunction_and_metabolic_reprogramming
    L_2_hydroxyglutarate_accumulation --&gt; Epigenetic_dysregulation_via_inhibition_of_alpha_KG_dependent_dioxygenases

    style White_matter_vulnerability_and_progressive_leukoencephalopathy fill:#dbeafe
    style L2HGDH_enzymatic_deficiency fill:#dbeafe
    style Mitochondrial_dysfunction_and_metabolic_reprogramming fill:#dbeafe
    style L_2_hydroxyglutarate_accumulation fill:#dbeafe
    style Epigenetic_dysregulation_via_inhibition_of_alpha_KG_dependent_dioxygenases fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">14</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Head and Neck<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Nervous System<span class="pill-count">(10)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Neoplasm<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Other<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Macrocephaly
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000256" target="_blank">
                                Macrocephaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000256)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24321868" target="_blank">PMID:24321868</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Macrocephaly is present in half of the cases."</div>
                
                
                <div class="evidence-explanation">Reports macrocephaly in approximately 50% of L2HGA cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Spasticity
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001257" target="_blank">
                                Spasticity
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001257)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Exaggerated tendon reflexes and bilateral sustained ankle clonus were observed in addition to cerebellar signs."</div>
                
                
                <div class="evidence-explanation">Upper motor neuron signs consistent with spasticity were present in both patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Brisk deep tendon reflexes, clonus, and bilateral Babinski signs were present."</div>
                
                
                <div class="evidence-explanation">Pyramidal signs documented in the DBS case report.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">10</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Intellectual disability
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001249" target="_blank">
                                Intellectual disability
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001249)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"L-2-hydroxyglutaric aciduria (L2HGA) is an autosomal recessive, slowly progressive neurodegenerative disease characterized by psychomotor delay and cerebellar dysfunction."</div>
                
                
                <div class="evidence-explanation">Psychomotor delay leading to intellectual disability is a defining feature of L2HGA.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common clinical symptoms were developmental delay, intellectual disability, and movement disorders."</div>
                
                
                <div class="evidence-explanation">Confirms intellectual disability as one of the most common symptoms in a Turkish cohort.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Psychomotor retardation
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001263" target="_blank">
                                Global developmental delay
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001263)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"L-2-hydroxyglutaric aciduria (L2HGA) is an autosomal recessive, slowly progressive neurodegenerative disease characterized by psychomotor delay and cerebellar dysfunction."</div>
                
                
                <div class="evidence-explanation">Psychomotor delay is listed as a defining characteristic.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Seizures
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                                Seizure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001250)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria."</div>
                
                
                <div class="evidence-explanation">Seizures are part of the core clinical presentation described in this case series.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24321868" target="_blank">PMID:24321868</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It occurs in childhood with mental retardation, cerebellar ataxia, and epilepsy."</div>
                
                
                <div class="evidence-explanation">Confirms epilepsy as a core feature of L2HGA alongside mental retardation and cerebellar ataxia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cerebellar ataxia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001251" target="_blank">
                                Ataxia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001251)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"L-2-hydroxyglutaric aciduria (L2HGA) is an autosomal recessive, slowly progressive neurodegenerative disease characterized by psychomotor delay and cerebellar dysfunction."</div>
                
                
                <div class="evidence-explanation">Cerebellar dysfunction is described as a defining feature of L2HGA.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria."</div>
                
                
                <div class="evidence-explanation">Ataxia was present in both patients in this case series.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dystonia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001332" target="_blank">
                                Dystonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001332)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred speech, bilateral dysmetria, and a wide-based gait."</div>
                
                
                <div class="evidence-explanation">Describes generalized dystonia in a patient with L2HGA requiring DBS intervention.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Following minimal response to pharmacotherapy, GPi-DBS was performed."</div>
                
                
                <div class="evidence-explanation">Documents that dystonia in L2HGA can be pharmacoresistant, confirming its clinical significance as a distinct movement disorder phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dysarthria
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001260" target="_blank">
                                Dysarthria
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001260)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria."</div>
                
                
                <div class="evidence-explanation">Dysarthria was present in both reported patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred speech, bilateral dysmetria, and a wide-based gait."</div>
                
                
                <div class="evidence-explanation">Slurred speech observed in the DBS case report patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Subcortical leukoencephalopathy
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002352" target="_blank">
                                Leukoencephalopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002352)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Brain MRI of the 15-year-old showed diffuse subcortical white matter changes evident by T2/FLAIR hyperintense signals bilaterally, particularly in the frontal region in the centripetal distribution"</div>
                
                
                <div class="evidence-explanation">Describes the characteristic centripetal subcortical white matter MRI pattern.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neuroradiological features of centripetal subcortical leukoencephalopathy with basal ganglia and dentate nuclei involvement are rather specific to L2HGA"</div>
                
                
                <div class="evidence-explanation">Confirms the diagnostic specificity of the MRI pattern.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Behavioral abnormality
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000708" target="_blank">
                                Atypical behavior
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000708)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Behavioural problems were more common in L2HGA than in GA-I patients."</div>
                
                
                <div class="evidence-explanation">Documents increased behavioral problems in L2HGA compared to glutaric aciduria type I.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chorea
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002072" target="_blank">
                                Chorea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002072)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred speech, bilateral dysmetria, and a wide-based gait."</div>
                
                
                <div class="evidence-explanation">Choreic movements were documented in the DBS case report patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Gait ataxia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002066" target="_blank">
                                Gait ataxia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002066)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred speech, bilateral dysmetria, and a wide-based gait."</div>
                
                
                <div class="evidence-explanation">Wide-based gait documented in L2HGA patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Neoplasm
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        CNS neoplasm
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100836" target="_blank">
                                Malignant neoplasm of the central nervous system
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100836)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38716347" target="_blank">PMID:38716347</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"L-2-HGA patients have a significantly increased lifetime risk of central nervous system (CNS) tumors."</div>
                
                
                <div class="evidence-explanation">Directly states increased CNS tumor risk in L2HGA patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Intention tremor
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002080" target="_blank">
                                Intention tremor
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002080)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria."</div>
                
                
                <div class="evidence-explanation">Intentional tremors documented in both patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    L2HGDH variants
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22391998" target="_blank">PMID:22391998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We report on the clinical, genetic, enzymatic and metabolic characterization of D-2-HGA type I, D-2-HGA type II, L-2-HGA and D,L-2-HGA"</div>
                
                
                <div class="evidence-explanation">Comprehensive review of genetic, enzymatic, and metabolic characterization of L2HGA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Riboflavin supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Riboflavin (vitamin B2), the precursor of FAD cofactor required by L2HGDH, is the cornerstone therapy for L2HGA. FAD supplementation aims to enhance any residual enzyme activity and accelerate conversion of L-2-HG to alpha-ketoglutarate. In cohort studies, riboflavin combined with levocarnitine produced significant decreases in urinary 2-HG levels and limited neurologic improvement.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In all L2HGA patients, there was a significant decrease in the mean urinary 2- hydoxy glutarate with treatment."</div>
                
                
                <div class="evidence-explanation">Demonstrates significant biochemical response to riboflavin/levocarnitine in L2HGA cohort.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Relative neurologic improvement was seen in three L2HGA patients."</div>
                
                
                <div class="evidence-explanation">Documents some clinical improvement with riboflavin-based treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24321868" target="_blank">PMID:24321868</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Under specific treatment, the progression of the disease was subsequently stopped."</div>
                
                
                <div class="evidence-explanation">Reports halting of disease progression under riboflavin treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Levocarnitine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Levocarnitine is used alongside riboflavin as part of standard metabolic therapy for L2HGA. It supports organic acid detoxification and excretion pathways.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Current treatment strategies are based on levocarnitine, vitamin B2, and diet."</div>
                
                
                <div class="evidence-explanation">Confirms levocarnitine as a component of standard treatment for L2HGA.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In L2HGA patients, we used levocarnitine and vitamin B2."</div>
                
                
                <div class="evidence-explanation">Documents use of levocarnitine in all L2HGA patients in this cohort.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antiepileptic therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Seizure management with appropriate antiepileptic drugs is an important component of symptomatic care in L2HGA patients with epilepsy.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24321868" target="_blank">PMID:24321868</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It occurs in childhood with mental retardation, cerebellar ataxia, and epilepsy."</div>
                
                
                <div class="evidence-explanation">Epilepsy is a core feature of L2HGA, necessitating antiepileptic pharmacotherapy as part of symptomatic management.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria."</div>
                
                
                <div class="evidence-explanation">Both patients in this case series had seizures, supporting the need for antiepileptic therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Deep brain stimulation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Bilateral globus pallidus internus deep brain stimulation (GPi-DBS) has been used for L2HGA-related refractory dystonia with reported significant improvements in mobility and dystonia severity. This represents an emerging intervention for severe, pharmacoresistant movement disorders in L2HGA.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Significant increases in mobility and decrease in dystonia were observed at 3 weeks, 6 months, and 12 months postoperatively."</div>
                
                
                <div class="evidence-explanation">Documents significant improvement with GPi-DBS in L2HGA-related dystonia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This is the first utilization of DBS as treatment for L2HGA-related dystonia."</div>
                
                
                <div class="evidence-explanation">Establishes GPi-DBS as a novel therapeutic option for L2HGA dystonia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive care and rehabilitation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Comprehensive supportive care including physical therapy, occupational therapy, speech therapy, and educational support is essential for managing the chronic neurological disabilities of L2HGA.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Relative neurologic improvement was seen in three L2HGA patients."</div>
                
                
                <div class="evidence-explanation">Some patients show improvement with comprehensive treatment approach, supporting role of ongoing supportive care.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling for affected families addressing autosomal recessive inheritance, 25% recurrence risk, carrier testing for at-risk relatives, and prenatal/preimplantation testing options. Consanguinity is a significant factor in many reported families.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Both parents were heterozygous carriers of the familial variant."</div>
                
                
                <div class="evidence-explanation">Carrier status in parents supports autosomal recessive counseling approach.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Dietary intervention
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dietary management may be employed as part of the treatment approach, though the evidence base is less established than for other organic acidemias. Unlike glutaric aciduria type I, there is no specific amino acid restriction protocol for L2HGA.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37275239" target="_blank">PMID:37275239</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Current treatment strategies are based on levocarnitine, vitamin B2, and diet."</div>
                
                
                <div class="evidence-explanation">Diet is listed as one component of current treatment strategies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Neuroimaging surveillance
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Regular brain MRI monitoring to track disease progression and to screen for CNS tumor development, given the elevated tumor risk in L2HGA patients. MR spectroscopy can provide additional metabolic information.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38716347" target="_blank">PMID:38716347</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"L-2-HGA patients have a significantly increased lifetime risk of central nervous system (CNS) tumors."</div>
                
                
                <div class="evidence-explanation">Increased CNS tumor risk mandates ongoing neuroimaging surveillance.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    L-2-hydroxyglutaric acid (urine)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Urinary L-2-hydroxyglutaric acid is markedly elevated (10-300 fold above normal) and is the primary diagnostic biomarker for L2HGA. Chiral differentiation is needed to distinguish L from D enantiomer.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22391998" target="_blank">PMID:22391998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical hallmarks of these disorders."</div>
                
                
                <div class="evidence-explanation">Establishes L-2-HG accumulation in body fluids as the biochemical hallmark.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37113859" target="_blank">PMID:37113859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Urine organic acids analysis showed marked excretion of 2-hydroxyglutaric acid, chiral differentiation of 2-hydroxyglutaric acid showed it to be L2HGA."</div>
                
                
                <div class="evidence-explanation">Confirms elevated urinary L-2-HG with chiral differentiation establishing the L-enantiomer.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    L-2-hydroxyglutaric acid (CSF)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: CSF L-2-HG is elevated with a CSF/plasma ratio that may exceed 1, consistent with preferential brain accumulation. CSF analysis provides additional diagnostic value and reflects the degree of CNS metabolite burden.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22391998" target="_blank">PMID:22391998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical hallmarks of these disorders."</div>
                
                
                <div class="evidence-explanation">CSF is one of the body fluids in which L-2-HG accumulates.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28137912" target="_blank">PMID:28137912</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"The highest levels of L-2-HG were observed in the brain and testis"</div>
                
                
                <div class="evidence-explanation">Mouse model demonstrates preferential brain accumulation supporting elevated CSF levels.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    L-2-hydroxyglutaric acid (plasma)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Plasma L-2-HG levels are elevated in L2HGA but typically to a lesser degree than urinary and CSF concentrations. Plasma analysis can support diagnosis alongside urine organic acid studies.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22391998" target="_blank">PMID:22391998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical hallmarks of these disorders."</div>
                
                
                <div class="evidence-explanation">Plasma is one of the body fluids in which L-2-HG is elevated.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    N-acetylaspartate (brain MRS)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Proton MR spectroscopy shows decreased N-acetylaspartate (NAA) in affected brain regions, reflecting neuronal loss or dysfunction. An additional metabolite peak at approximately 2.50 ppm attributable to L-2-hydroxyglutaric acid may be detected.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26610379" target="_blank">PMID:26610379</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Metabolic disturbances lead to alterations in cellular function as well as microscopic and macroscopic structural changes in the brain"</div>
                
                
                <div class="evidence-explanation">General review of NMR findings in hereditary metabolic disorders; provides indirect context for MRS-detectable changes in L2HGA but does not specifically discuss NAA alterations in L2HGA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Urinary 2-OH-glutaric acid
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Significantly elevated urine 2-OH-glutaric acid level is a key diagnostic finding. The metabolite is detectable by standard urine organic acid chromatography and confirmable by chiral analysis.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38714179" target="_blank">PMID:38714179</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Urine 2-OH-glutaric acid level was significantly elevated."</div>
                
                
                <div class="evidence-explanation">Documents significantly elevated urinary 2-OH-glutaric acid in an L2HGA patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: L-2-Hydroxyglutaric Aciduria
category: Mendelian
creation_date: &#39;2025-06-12T20:16:27Z&#39;
updated_date: &#39;2026-02-28T02:54:00Z&#39;
synonyms:
- L2HGA
- L-2-HGA
- L-2-hydroxyglutaric acidemia
- L2HGDH deficiency
description: &#39;L-2-Hydroxyglutaric aciduria (L2HGA) is a rare autosomal recessive neurometabolic disorder caused by biallelic
  pathogenic variants in the L2HGDH gene, which encodes a mitochondrial FAD-dependent L-2-hydroxyglutarate dehydrogenase.
  Loss of this metabolite-repair enzyme leads to systemic accumulation of L-2-hydroxyglutarate (L-2-HG), particularly in the
  brain and cerebrospinal fluid. The disease follows a slowly progressive course characterized by psychomotor delay, intellectual
  disability, epilepsy, cerebellar ataxia, and movement disorders. Brain MRI shows a distinctive pattern of subcortical white
  matter abnormalities with basal ganglia and dentate nuclei involvement. L2HGA patients also have an increased lifetime risk
  of central nervous system tumors. Treatment is primarily supportive with riboflavin and levocarnitine supplementation.

  &#39;
disease_term:
  preferred_term: L-2-hydroxyglutaric aciduria
  term:
    id: MONDO:0009370
    label: L-2-hydroxyglutaric aciduria
parents:
- Organic Acidemia
- Inborn Error of Metabolism
prevalence:
- population: Global
  notes: &#39;L2HGA is a rare disorder. Fewer than 300 cases have been reported worldwide. Higher prevalence is observed in populations
    with high consanguinity rates.

    &#39;
progression:
- phase: Onset
  age_range: Infancy-Early childhood
  notes: &#39;L2HGA typically presents in early childhood with developmental delay. Unlike many organic acidemias, L2HGA does
    not feature acute metabolic decompensation crises. Disease progression is insidious, with gradual neurological deterioration
    over years to decades including progressive cerebellar dysfunction, epilepsy, and movement disorders.

    &#39;
pathophysiology:
- name: L2HGDH enzymatic deficiency
  description: &#39;Pathogenic variants in L2HGDH reduce mitochondrial L-2-hydroxyglutarate dehydrogenase activity.

    &#39;
  genes:
  - preferred_term: L2HGDH
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  downstream:
  - target: L-2-hydroxyglutarate accumulation
    description: Loss of L2HGDH metabolite-repair activity causes progressive L-2-HG buildup in body fluids and brain.
- name: L-2-hydroxyglutarate accumulation
  description: &#39;Loss of L-2-hydroxyglutarate dehydrogenase activity impairs the metabolite-repair pathway that clears L-2-hydroxyglutarate
    (L-2-HG), an aberrant off-pathway metabolite produced from alpha-ketoglutarate by L-malate dehydrogenase. L-2-HG accumulates
    in body fluids, particularly brain and CSF, at concentrations 10-300 times above normal.

    &#39;
  biological_processes:
  - preferred_term: organic acid metabolic process
    term:
      id: GO:0006082
      label: organic acid metabolic process
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:22391998
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical
      hallmarks of these disorders.
    explanation: Directly supports L-2-HG accumulation as the biochemical hallmark of L2HGA.
  downstream:
  - target: White-matter vulnerability and progressive leukoencephalopathy
    description: Chronic L-2-HG elevation drives selective white-matter injury and neuroinflammatory remodeling.
  - target: Mitochondrial dysfunction and metabolic reprogramming
    description: L-2-HG perturbs mitochondrial bioenergetics and shifts cellular metabolism toward anaerobic pathways.
  - target: Epigenetic dysregulation via inhibition of alpha-KG-dependent dioxygenases
    description: L-2-HG can interfere with alpha-KG-dependent chromatin enzymes, altering epigenetic regulation.
- name: White-matter vulnerability and progressive leukoencephalopathy
  description: &#39;L-2-HG accumulation leads to selective vulnerability of subcortical cerebral white matter with basal ganglia
    and dentate nucleus involvement. In mouse models, L2HGDH deficiency causes progressive leukoencephalopathy with demyelination,
    extensive gliosis, microglia-mediated neuroinflammation, and expansion of oligodendrocyte progenitor cells.

    &#39;
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  locations:
  - preferred_term: white matter
    term:
      id: UBERON:0002316
      label: white matter
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  evidence:
  - reference: PMID:28137912
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: KO mice exhibit white matter abnormalities, extensive gliosis, microglia-mediated neuroinflammation, and an expansion
      of oligodendrocyte progenitor cells (OPCs).
    explanation: Mouse model demonstrates leukoencephalopathy, gliosis, neuroinflammation, and OPC expansion.
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neuroradiological features of centripetal subcortical leukoencephalopathy with basal ganglia and dentate nuclei
      involvement are rather specific to L2HGA
    explanation: Human neuroimaging confirms the characteristic white matter and deep gray matter pattern.
- name: Mitochondrial dysfunction and metabolic reprogramming
  description: &#39;Elevated L-2-HG impairs mitochondrial bioenergetics, reducing maximal respiratory capacity and shifting neuronal
    cell metabolism toward anaerobic glycolysis. In neuronal cell models, L-2-HG exposure leads to decreased glucose uptake,
    increased lactate release, and reduced carbon flux through the TCA cycle.

    &#39;
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: glycolytic process
    term:
      id: GO:0006096
      label: glycolytic process
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:38862727
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: both enantiomers of 2HG comparably stimulate anaerobic metabolism of glucose and inhibit the uptake of several
      essential amino acids from the culture media
    explanation: In vitro neuronal cell model demonstrates metabolic reprogramming under L-2-HG exposure.
- name: Epigenetic dysregulation via inhibition of alpha-KG-dependent dioxygenases
  description: &#39;L-2-HG is a structural analog of alpha-ketoglutarate and can inhibit alpha-KG-dependent dioxygenases, including
    TET DNA hydroxylases and JmjC histone demethylases. In L2HGDH-deficient mouse brain, this manifests as increased histone
    methylation, linking metabolite accumulation to epigenetic perturbation.

    &#39;
  biological_processes:
  - preferred_term: histone demethylation
    term:
      id: GO:0016577
      label: histone demethylation
  - preferred_term: DNA demethylation
    term:
      id: GO:0080111
      label: DNA demethylation
  locations:
  - preferred_term: nucleus
    term:
      id: GO:0005634
      label: nucleus
  evidence:
  - reference: PMID:38716347
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: These findings were against all our expectations given the inhibitory potential of 2-HG on DNA-demethylation
      enzymes.
    explanation: L-2-HGA-associated glioma did NOT show the G-CIMP hypermethylation phenotype
      expected from dioxygenase inhibition, unlike IDH-mutant tumors with D-2-HG accumulation.
      This argues against a simple epigenetic oncogenic mechanism in L-2-HGA.
  - reference: PMID:28137912
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: a corresponding increase in histone methylation in these tissues
    explanation: L2hgdh KO mice show increased histone methylation in brain, directly
      demonstrating that L-2-HG accumulation causes epigenetic dysregulation via inhibition
      of histone demethylases in vivo.
phenotypes:
- name: Intellectual disability
  frequency: VERY_FREQUENT
  description: &#39;Intellectual disability is present in the majority of L2HGA patients. Severity ranges from mild to severe
    and is progressive.

    &#39;
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: L-2-hydroxyglutaric aciduria (L2HGA) is an autosomal recessive, slowly progressive neurodegenerative disease
      characterized by psychomotor delay and cerebellar dysfunction.
    explanation: Psychomotor delay leading to intellectual disability is a defining feature of L2HGA.
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common clinical symptoms were developmental delay, intellectual disability, and movement disorders.
    explanation: Confirms intellectual disability as one of the most common symptoms in a Turkish cohort.
- name: Psychomotor retardation
  frequency: VERY_FREQUENT
  description: &#39;Delayed motor and cognitive milestones are typically the earliest presenting features of L2HGA in childhood.

    &#39;
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: L-2-hydroxyglutaric aciduria (L2HGA) is an autosomal recessive, slowly progressive neurodegenerative disease
      characterized by psychomotor delay and cerebellar dysfunction.
    explanation: Psychomotor delay is listed as a defining characteristic.
- name: Seizures
  frequency: FREQUENT
  description: &#39;Epilepsy occurs in a significant proportion of L2HGA patients, with seizures reported in 30-75% of cases across
    different cohorts. Seizure types are variable.

    &#39;
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria.
    explanation: Seizures are part of the core clinical presentation described in this case series.
  - reference: PMID:24321868
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It occurs in childhood with mental retardation, cerebellar ataxia, and epilepsy.
    explanation: Confirms epilepsy as a core feature of L2HGA alongside mental retardation and cerebellar ataxia.
- name: Cerebellar ataxia
  frequency: VERY_FREQUENT
  description: &#39;Cerebellar ataxia is a hallmark feature of L2HGA, correlating with dentate nucleus and cerebellar white matter
    involvement on MRI. It manifests as gait instability, dysmetria, and intention tremor.

    &#39;
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: L-2-hydroxyglutaric aciduria (L2HGA) is an autosomal recessive, slowly progressive neurodegenerative disease
      characterized by psychomotor delay and cerebellar dysfunction.
    explanation: Cerebellar dysfunction is described as a defining feature of L2HGA.
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria.
    explanation: Ataxia was present in both patients in this case series.
- name: Dystonia
  frequency: FREQUENT
  description: &#39;Generalized dystonia occurs in L2HGA, relating to basal ganglia involvement. In severe cases, dystonia may
    be refractory to pharmacotherapy and require deep brain stimulation.

    &#39;
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred
      speech, bilateral dysmetria, and a wide-based gait.
    explanation: Describes generalized dystonia in a patient with L2HGA requiring DBS intervention.
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Following minimal response to pharmacotherapy, GPi-DBS was performed.
    explanation: Documents that dystonia in L2HGA can be pharmacoresistant, confirming its clinical significance as a distinct movement disorder phenotype.
- name: Dysarthria
  frequency: FREQUENT
  description: &#39;Speech difficulties including slurred speech are common in L2HGA, related to cerebellar and basal ganglia
    dysfunction.

    &#39;
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria.
    explanation: Dysarthria was present in both reported patients.
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred
      speech, bilateral dysmetria, and a wide-based gait.
    explanation: Slurred speech observed in the DBS case report patient.
- name: Macrocephaly
  frequency: FREQUENT
  description: &#39;Macrocephaly has been reported in approximately 50-75% of L2HGA patients in various cohorts and is a useful
    diagnostic clue.

    &#39;
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:24321868
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Macrocephaly is present in half of the cases.
    explanation: Reports macrocephaly in approximately 50% of L2HGA cases.
- name: Subcortical leukoencephalopathy
  frequency: VERY_FREQUENT
  description: &#39;Brain MRI shows a characteristic pattern of subcortical white matter T2/FLAIR hyperintensity in a centripetal
    distribution, particularly involving the U-fibers, along with basal ganglia and dentate nuclei signal abnormalities. This
    pattern is highly specific for L2HGA.

    &#39;
  phenotype_term:
    preferred_term: Leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
  diagnostic: true
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Brain MRI of the 15-year-old showed diffuse subcortical white matter changes evident by T2/FLAIR hyperintense
      signals bilaterally, particularly in the frontal region in the centripetal distribution
    explanation: Describes the characteristic centripetal subcortical white matter MRI pattern.
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neuroradiological features of centripetal subcortical leukoencephalopathy with basal ganglia and dentate nuclei
      involvement are rather specific to L2HGA
    explanation: Confirms the diagnostic specificity of the MRI pattern.
- name: Spasticity
  frequency: FREQUENT
  description: &#39;Upper motor neuron signs including exaggerated tendon reflexes, clonus, and Babinski signs are common in L2HGA,
    reflecting corticospinal tract involvement.

    &#39;
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Exaggerated tendon reflexes and bilateral sustained ankle clonus were observed in addition to cerebellar signs.
    explanation: Upper motor neuron signs consistent with spasticity were present in both patients.
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Brisk deep tendon reflexes, clonus, and bilateral Babinski signs were present.
    explanation: Pyramidal signs documented in the DBS case report.
- name: Intention tremor
  frequency: FREQUENT
  description: &#39;Intention tremor is a cerebellar sign commonly observed in L2HGA, reflecting cerebellar and dentate nucleus
    dysfunction.

    &#39;
  phenotype_term:
    preferred_term: Intention tremor
    term:
      id: HP:0002080
      label: Intention tremor
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria.
    explanation: Intentional tremors documented in both patients.
- name: Behavioral abnormality
  frequency: FREQUENT
  description: &#39;Behavioral problems are commonly reported in L2HGA patients and may be more prevalent than in other cerebral
    organic acidurias.

    &#39;
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Behavioural problems were more common in L2HGA than in GA-I patients.
    explanation: Documents increased behavioral problems in L2HGA compared to glutaric aciduria type I.
- name: Chorea
  frequency: OCCASIONAL
  description: &#39;Choreic movements may occur in L2HGA, particularly affecting the upper extremities, as part of the extrapyramidal
    movement disorder spectrum.

    &#39;
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  evidence:
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred
      speech, bilateral dysmetria, and a wide-based gait.
    explanation: Choreic movements were documented in the DBS case report patient.
- name: Gait ataxia
  frequency: FREQUENT
  description: &#39;Wide-based and unsteady gait is a common manifestation of cerebellar dysfunction in L2HGA.

    &#39;
  phenotype_term:
    preferred_term: Gait ataxia
    term:
      id: HP:0002066
      label: Gait ataxia
  evidence:
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neurological exam revealed generalized dystonia, significant choreic movements in the upper extremities, slurred
      speech, bilateral dysmetria, and a wide-based gait.
    explanation: Wide-based gait documented in L2HGA patient.
- name: CNS neoplasm
  frequency: VERY_RARE
  description: &#39;L2HGA patients have a significantly increased lifetime risk of central nervous system tumors, including malignant
    glioma. Despite the theoretical epigenetic effects of L-2-HG on TET enzymes, L2HGA- associated tumors do not typically
    show IDH-mutant-like methylation profiles, suggesting a distinct oncogenetic mechanism.

    &#39;
  phenotype_term:
    preferred_term: Malignant neoplasm of the central nervous system
    term:
      id: HP:0100836
      label: Malignant neoplasm of the central nervous system
  evidence:
  - reference: PMID:38716347
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: L-2-HGA patients have a significantly increased lifetime risk of central nervous system (CNS) tumors.
    explanation: Directly states increased CNS tumor risk in L2HGA patients.
biochemical:
- name: L-2-hydroxyglutaric acid (urine)
  presence: INCREASED
  context: &#39;Urinary L-2-hydroxyglutaric acid is markedly elevated (10-300 fold above normal) and is the primary diagnostic
    biomarker for L2HGA. Chiral differentiation is needed to distinguish L from D enantiomer.

    &#39;
  evidence:
  - reference: PMID:22391998
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical
      hallmarks of these disorders.
    explanation: Establishes L-2-HG accumulation in body fluids as the biochemical hallmark.
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Urine organic acids analysis showed marked excretion of 2-hydroxyglutaric acid, chiral differentiation of 2-hydroxyglutaric
      acid showed it to be L2HGA.
    explanation: Confirms elevated urinary L-2-HG with chiral differentiation establishing the L-enantiomer.
- name: L-2-hydroxyglutaric acid (CSF)
  presence: INCREASED
  context: &#39;CSF L-2-HG is elevated with a CSF/plasma ratio that may exceed 1, consistent with preferential brain accumulation.
    CSF analysis provides additional diagnostic value and reflects the degree of CNS metabolite burden.

    &#39;
  evidence:
  - reference: PMID:22391998
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical
      hallmarks of these disorders.
    explanation: CSF is one of the body fluids in which L-2-HG accumulates.
  - reference: PMID:28137912
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The highest levels of L-2-HG were observed in the brain and testis
    explanation: Mouse model demonstrates preferential brain accumulation supporting elevated CSF levels.
- name: L-2-hydroxyglutaric acid (plasma)
  presence: INCREASED
  context: &#39;Plasma L-2-HG levels are elevated in L2HGA but typically to a lesser degree than urinary and CSF concentrations.
    Plasma analysis can support diagnosis alongside urine organic acid studies.

    &#39;
  evidence:
  - reference: PMID:22391998
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Accumulation of D-2-hydroxyglutarate (D-2-HG) and/or L-2-hydroxyglutarate (L-2-HG) in body fluids are the biochemical
      hallmarks of these disorders.
    explanation: Plasma is one of the body fluids in which L-2-HG is elevated.
- name: N-acetylaspartate (brain MRS)
  presence: DECREASED
  context: &#39;Proton MR spectroscopy shows decreased N-acetylaspartate (NAA) in affected brain regions, reflecting neuronal
    loss or dysfunction. An additional metabolite peak at approximately 2.50 ppm attributable to L-2-hydroxyglutaric acid
    may be detected.

    &#39;
  evidence:
  - reference: PMID:26610379
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Metabolic disturbances lead to alterations in cellular function as well as microscopic and macroscopic structural
      changes in the brain
    explanation: General review of NMR findings in hereditary metabolic disorders; provides indirect context for MRS-detectable
      changes in L2HGA but does not specifically discuss NAA alterations in L2HGA.
- name: Urinary 2-OH-glutaric acid
  presence: INCREASED
  context: &#39;Significantly elevated urine 2-OH-glutaric acid level is a key diagnostic finding. The metabolite is detectable
    by standard urine organic acid chromatography and confirmable by chiral analysis.

    &#39;
  evidence:
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Urine 2-OH-glutaric acid level was significantly elevated.
    explanation: Documents significantly elevated urinary 2-OH-glutaric acid in an L2HGA patient.
genetic:
- name: L2HGDH variants
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:37113859
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: L-2-hydroxyglutaric aciduria (L2HGA) is an autosomal recessive, slowly progressive neurodegenerative disease
      explanation: Directly states autosomal recessive inheritance.
  variants:
  - name: c.829C&gt;T (p.Arg227*)
    description: &#39;Nonsense variant creating a premature stop codon, identified in a consanguineous Pakistani family. Both
      affected sisters were homozygous.

      &#39;
  - name: c.164G&gt;A (p.Gly55Asp)
    description: &#39;Missense variant affecting a conserved glycine residue, identified in a patient with severe dystonia requiring
      DBS intervention.

      &#39;
  - name: c.407delA and c.699_700insA compound heterozygous
    description: &#39;Compound heterozygous frameshift mutations leading to premature termination codons and truncated FAD/NAD(P)-binding
      domain. Identified in a Chinese patient with psychomotor retardation and progressive ataxia.

      &#39;
    evidence:
    - reference: PMID:29980873
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Next-generation sequencing (NGS) revealed two novel compound heterozygous frameshift mutations, c.407 del A
        (p.K136SfsTer3) and c.699_c700 ins A (p.D234RfsTer42), in the L-2-hydroxyglutarate dehydrogenase (L2HGDH) gene
      explanation: Documents compound heterozygous variants disrupting the FAD-binding domain.
  features: &#39;L2HGDH encodes a mitochondrial FAD-dependent enzyme that catalyzes oxidation of L-2-hydroxyglutarate to alpha-ketoglutarate.
    Biallelic pathogenic variants including missense, nonsense, frameshift, and splice site mutations have been reported.
    The enzyme functions as a metabolite-repair enzyme clearing an aberrant byproduct of L-malate dehydrogenase activity.
    Consanguinity is a significant risk factor given the autosomal recessive inheritance.

    &#39;
  evidence:
  - reference: PMID:22391998
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We report on the clinical, genetic, enzymatic and metabolic characterization of D-2-HGA type I, D-2-HGA type
      II, L-2-HGA and D,L-2-HGA
    explanation: Comprehensive review of genetic, enzymatic, and metabolic characterization of L2HGA.
treatments:
- name: Riboflavin supplementation
  description: &#39;Riboflavin (vitamin B2), the precursor of FAD cofactor required by L2HGDH, is the cornerstone therapy for
    L2HGA. FAD supplementation aims to enhance any residual enzyme activity and accelerate conversion of L-2-HG to alpha-ketoglutarate.
    In cohort studies, riboflavin combined with levocarnitine produced significant decreases in urinary 2-HG levels and limited
    neurologic improvement.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In all L2HGA patients, there was a significant decrease in the mean urinary 2- hydoxy glutarate with treatment.
    explanation: Demonstrates significant biochemical response to riboflavin/levocarnitine in L2HGA cohort.
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Relative neurologic improvement was seen in three L2HGA patients.
    explanation: Documents some clinical improvement with riboflavin-based treatment.
  - reference: PMID:24321868
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Under specific treatment, the progression of the disease was subsequently stopped.
    explanation: Reports halting of disease progression under riboflavin treatment.
- name: Levocarnitine supplementation
  description: &#39;Levocarnitine is used alongside riboflavin as part of standard metabolic therapy for L2HGA. It supports organic
    acid detoxification and excretion pathways.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Current treatment strategies are based on levocarnitine, vitamin B2, and diet.
    explanation: Confirms levocarnitine as a component of standard treatment for L2HGA.
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In L2HGA patients, we used levocarnitine and vitamin B2.
    explanation: Documents use of levocarnitine in all L2HGA patients in this cohort.
- name: Antiepileptic therapy
  description: &#39;Seizure management with appropriate antiepileptic drugs is an important component of symptomatic care in L2HGA
    patients with epilepsy.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:24321868
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It occurs in childhood with mental retardation, cerebellar ataxia, and epilepsy.
    explanation: Epilepsy is a core feature of L2HGA, necessitating antiepileptic pharmacotherapy as part of symptomatic management.
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 15- and 17-year-old girls presented with psychomotor delay, seizures, ataxia, intentional tremors, and dysarthria.
    explanation: Both patients in this case series had seizures, supporting the need for antiepileptic therapy.
- name: Deep brain stimulation
  description: &#39;Bilateral globus pallidus internus deep brain stimulation (GPi-DBS) has been used for L2HGA-related refractory
    dystonia with reported significant improvements in mobility and dystonia severity. This represents an emerging intervention
    for severe, pharmacoresistant movement disorders in L2HGA.

    &#39;
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Significant increases in mobility and decrease in dystonia were observed at 3 weeks, 6 months, and 12 months
      postoperatively.
    explanation: Documents significant improvement with GPi-DBS in L2HGA-related dystonia.
  - reference: PMID:38714179
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This is the first utilization of DBS as treatment for L2HGA-related dystonia.
    explanation: Establishes GPi-DBS as a novel therapeutic option for L2HGA dystonia.
- name: Supportive care and rehabilitation
  description: &#39;Comprehensive supportive care including physical therapy, occupational therapy, speech therapy, and educational
    support is essential for managing the chronic neurological disabilities of L2HGA.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Relative neurologic improvement was seen in three L2HGA patients.
    explanation: Some patients show improvement with comprehensive treatment approach, supporting role of ongoing supportive
      care.
- name: Genetic counseling
  description: &#39;Genetic counseling for affected families addressing autosomal recessive inheritance, 25% recurrence risk,
    carrier testing for at-risk relatives, and prenatal/preimplantation testing options. Consanguinity is a significant factor
    in many reported families.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:37113859
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Both parents were heterozygous carriers of the familial variant.
    explanation: Carrier status in parents supports autosomal recessive counseling approach.
- name: Dietary intervention
  description: &#39;Dietary management may be employed as part of the treatment approach, though the evidence base is less established
    than for other organic acidemias. Unlike glutaric aciduria type I, there is no specific amino acid restriction protocol
    for L2HGA.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:37275239
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Current treatment strategies are based on levocarnitine, vitamin B2, and diet.
    explanation: Diet is listed as one component of current treatment strategies.
- name: Neuroimaging surveillance
  description: &#39;Regular brain MRI monitoring to track disease progression and to screen for CNS tumor development, given the
    elevated tumor risk in L2HGA patients. MR spectroscopy can provide additional metabolic information.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:38716347
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: L-2-HGA patients have a significantly increased lifetime risk of central nervous system (CNS) tumors.
    explanation: Increased CNS tumor risk mandates ongoing neuroimaging surveillance.
notes: &#39;L2HGA is classified as a disorder of metabolite repair rather than a classic enzyme-deficiency organic acidemia. Unlike
  most organic acidemias, L2HGA does not feature acute metabolic decompensation episodes. The disease was first described
  in 1980 and the causative gene L2HGDH was identified in 2004. The relationship between chronic L-2-HG accumulation and brain
  tumorigenesis is an active area of investigation, with emerging evidence suggesting a two-hit oncogenesis model where L-2-HG
  elevation may prime tissue for tumor development but a secondary somatic mutation is required.

  &#39;
references: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/L-2-Hydroxyglutaric_Aciduria.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>